Diabetes · 2023 · 17 citations · 38 references
Life SciencesEndocrinologyMolecular BiologyDiabetologyGene ExpressionInflammationDiabetes MellitusInflammatory SignalingInsulin ResistanceMicrorna BiologyMicrorna-mediated RegulationPancreatic EndocrinologyDiabetes Mellitus PathophysiologyGlucose-dependent Insulin SecretionGlucose-stimulated Insulin SecretionImpaired Glucose ToleranceImpaired Insulin SensitivityInflammation-associated Insulin ResistanceMitogen-activated Protein Kinase SignalingType 2 Diabetes Mellitus Pathogenesis
Chronic inflammation promotes pancreatic β-cell decompensation to insulin resistance because of local accumulation of supraphysiologic interleukin 1β (IL-1β) levels. However, the underlying molecular mechanisms remain elusive. We show that miR-503-5p is exclusively upregulated in islets from humans with type 2 diabetes and diabetic rodents because of its promoter hypomethylation and increased local IL-1β levels. β-Cell-specific miR-503 transgenic mice display mild or severe diabetes in a time- and expression-dependent manner. By contrast, deletion of the miR-503 cluster protects mice from high-fat diet-induced insulin resistance and glucose intolerance. Mechanistically, miR-503-5p represses c-Jun N-terminal kinase-interacting protein 2 (JIP2) translation to activate mitogen-activated protein kinase signaling cascades, thus inhibiting glucose-stimulated insulin secretion (GSIS) and compensatory β-cell proliferation. In addition, β-cell miR-503-5p is packaged in nanovesicles to dampen insulin signaling transduction in liver and adipose tissues by targeting insulin receptors. Notably, specifically blocking the miR-503 cluster in β-cells effectively remits aging-associated diabetes through recovery of GSIS capacity and insulin sensitivity. Our findings demonstrate that β-cell miR-503-5p is required for the development of insulin resistance and β-cell decompensation, providing a potential therapeutic target against diabetes. ARTICLE HIGHLIGHTS: Promoter hypomethylation during natural aging permits miR-503-5p overexpression in islets under inflammation conditions, conserving from rodents to humans. Impaired β-cells release nanovesicular miR-503-5p to accumulate in liver and adipose tissue, leading to their insulin resistance via the miR-503-5p/insulin receptor/phosphorylated AKT axis. Accumulated miR-503-5p in β-cells impairs glucose-stimulated insulin secretion via the JIP2-coordinated mitogen-activated protein kinase signaling cascades. Specific blockage of β-cell miR-503-5p improves β-cell function and glucose tolerance in aging mice.
38
Reassessment of Exosome Composition
Dennis K. Jeppesen, Aidan M. Fenix, Jeffrey L. Franklin et al. · Cell · 2019 · 2.9K citations · Full text
Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus
Claus M. Larsen, Mirjam Faulenbach, Allan Vaag et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text
A Cytoplasmic Inhibitor of the JNK Signal Transduction Pathway
Martin Dickens, Jeffrey S. Rogers, Julie Cavanagh et al. · Science · 1997 · 678 citations
A Mammalian Scaffold Complex That Selectively Mediates MAP Kinase Activation
Alan J. Whitmarsh, Julie Cavanagh, Cathy Tournier et al. · Science · 1998 · 656 citations
The JIP Group of Mitogen-Activated Protein Kinase Scaffold Proteins
Jun Yasuda, Alan J. Whitmarsh, Julie Cavanagh et al. · Molecular and Cellular Biology · 1999 · 468 citations